Vaxart Inc (NAS:VXRT)
$ 0.7303 0.0538 (7.95%) Market Cap: 129.57 Mil Enterprise Value: 102.71 Mil PE Ratio: 0 PB Ratio: 2.28 GF Score: 51/100

Q4 2023 Vaxart Inc Earnings Call Transcript

Mar 14, 2024 / 08:30PM GMT
Release Date Price: $1.1 (-2.65%)
Operator

Yes, greetings, and welcome to the Vaxart business update and full year 2023 financial results conference call. Question-and-answer session will follow management's opening remarks. Individual investors may submit written questions to ir.vaxart.com. As a reminder, this conference is being recorded. I would now like to turn the webcast over to your host, [Ed Burke], Senior Vice President and General Counsel.

Ed Burke
Vaxart, Inc. - SVP and General Counsel

Yes, good afternoon, and welcome to today's call. Joining us from Vaxart are Dr. Michael Finney, Interim Chief Executive Officer; Dr. Sean Tucker, Chief Scientific Officer; Dr. James Cummings, Chief Medical Officer; and Phil Lee, Chief Financial Officer. Before we begin, I would like to remind everyone that during this conference call, Vaxart may make forward-looking statements, including statements about the Company's financial results, financial guidance, its future business strategies and operations, and its product development and regulatory progress, including statements about its ongoing or planned

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot